Frozen copy retrieved 2026-08-20T19:10:00Z for audit 2026-08-20T21-09-12Z. Original URL: https://uk.finance.yahoo.com/news/moderna-co-founder-robert-langer-145852420.html. The Stochastic Parrot does not host or redistribute; this snapshot exists solely so that quoted spans remain verifiable if the original page changes. Character offsets below index into this plain text; highlighted spans are the quotes cited in the audit.

Moderna Co-Founder Robert Langer Is A Billionaire Again As Shares Double In Value

Forbes (staff writer Ty Roush; captured via Yahoo Finance UK syndication — forbes.com JS-blocked) · back to the audit

VERBATIM (Topline/Key Facts listicle format; fetch capped at 125 chars per fragment):

- Langer is "a billionaire once again" as Moderna shares "doubled on Wednesday after positive late-stage cancer vaccine trial results."
- Shares "rocketed by 156% to around $161" after "results from its first-ever late-stage trial of an experimental melanoma vaccine."
- The mRNA-based shot, combined with Merck's Keytruda, "marked the first successful final-stage study for an mRNA-based cancer therapy, reducing recurrence of severe skin cancer and extending time before melanoma returned."
- Langer "saw his equity in the biotech firm rise to about $1.7 billion" as of Wednesday, up from roughly $730 million on Tuesday.
- His stake "was estimated at $343 million when Moderna shares hit a low of $29.81 on Jan. 2."
- Fellow co-founder Noubar Afeyan's net worth jumped $184 million to $2.1 billion; CEO Stephane Bancel's fortune "swelled $2.5 billion to $4.8 billion"; founding investor Timothy Springer's rose by $948 million to an estimated $2.2 billion.
- Caption: "The biotech giant announced favorable results from a late-stage trial of a cancer vaccine."

AUDIT NOTE: The Forbes piece frames the story as a billionaire-wealth/stock story (156% / "$161"), not the clinical endpoints. It is by Ty Roush, NOT Sara Dorn (the roster hint was wrong). No overall-survival mention; no Trump-admin pushback; no clinical caveat beyond the share price.